Anteris Technologies Secures $23M For FDA Pivotal Heart Study

Anteris Technologies Ltd (ASX: AVR) has placed one million new ordinary shares at A$23 each, raising A$23 million before costs.

The funds will primarily be used for preparing the company’s transcatheter heart valve product for the Food and Drug Administration (FDA) pivotal study.

Its lead product is a transcatheter heart valve for treating aortic stenosis.

The FDA approval is a key step to gaining regulatory clearance for the U.S. market.

Funds will also be used for strategic initiatives, valve-in-valve trials, and general working capital.

Results to date

DurAVR™ has been implanted in 50 patients, including 44 with severe aortic stenosis and six valve-in-valve cases to rectify prosthetic valve failure.

Clinical results demonstrate this new class of biomimetic valves outperforms the market leader, returning patients to a near-normal haemodynamic (blood flow) state.

Biomimetic valve

DurAVR™ THV is a novel first-in-class biomimetic valve made from a single piece of native-shaped tissue.

The valve is designed to mimic the performance of a pre-disease human aortic valve.

Early data from the company’s First-in-Human clinical study show excellent haemodynamic performance at 12 months.

DurAVRTM THV is made using ADAPT® tissue, the company’s patented anti-calcification tissue technology.

ADAPT® tissue has been used clinically for over 10 years and distributed in over 55,000 patients worldwide.






JustStocks provides data and commentary that constitutes general information only. This does not constitute personal, financial, or professional advice or assistance. The data and information compiled do not consider your investment objectives or your financial circumstances. JustStocks cannot guarantee this website’s accuracy, completeness, or timeliness. JustStocks accepts no responsibility regarding any inaccuracy, omission, or change in information or articles or the data provided. The information published on this site/page should not be relied upon as a substitute for personal financial or professional advice. The information provided may not be appropriate for your circumstances or needs. JustStocks recommends that you seek professional advice from a qualified advisor before you make any decisions.

Articles of Interest